UBS Group
SYRS

UBS Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

UBS Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-240
Closed -$31K – 8321
2018
Q1 		$31K Hold
240
– – ﹤0.01% 6062
2017
Q4 		$23K Buy
+240
New +$32.2K ﹤0.01% 6456

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group's SYRS Position: Q1 2025 in Review

UBS Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 45,050 shares — an estimated $10.4K sold.

UBS Group first reported a position in SYRS in Q4 2016 and held it in 29 quarters. The position peaked at $307K in Q4 2019. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • UBS Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 45,050 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $10.4K.
  • UBS Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 29 quarters.
  • UBS Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $307K in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.